Exchange: NASDAQ·Updated 12:35 PM EDT
RGNX logo

RGNX Regenxbio Inc

$9.36
$0.04
(0.43%)
Today
Reported EarningsAug 6
Mkt Cap$615.24M
Vol204,369.00

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
45

Neutral Sentiment

How do you feel about RGNX?

Advertisement|Remove ads.